Toronto, Canada and Seoul, Korea – Cyclica Inc. (“Cyclica”), a neo-biotech with the vision to advance the most robust and sustainable drug discovery pipeline, and Oncocross Co., Ltd. (“Oncocross”), a biotech revolutionizing the drug development process through its unique AI approach based on transcriptome database, announce a drug discovery partnership to advance the development of oncology therapeutics. The partnership will initially focus on discovery and developing treatments for Myelofibrosis, with plans to expand to additional oncology areas.
“Combining forces with world class companies with complementary capabilities to ours is at the heart of Cyclica’s strategy. The combined strengths of the teams and platforms at Cyclica and Oncocross will lead to promising outcomes for the future of oncology medications, and we’re very enthusiastic about what this has the chance to mean for cancer patients”, shares Naheed Kurji, Co-Founder, President and CEO of Cyclica.
“We are very excited about this partnership with Cyclica, a global frontier in AI biotech space, where we put together innovative AI technologies that complement each other to yield a stronger outcome. This underlines our shared commitment to bring breakthrough solutions to cancer patients”, added Yi Rang KIM, Medical Oncologist, Founder and CEO of Oncocross.
“There is no “silver bullet” in AI drug discovery & development – a deep empathy for the complexity of biology and chemistry is required to achieve top results.
About Cyclica
Cyclica advances molecules that embrace the complexity of the disease. Our work spans dozens of collaborations with large pharma and biotech and several joint ventures. We are a passionate team of biotech and pharma professionals, biologists, chemists, and computer scientists who live and labour at the intersection of our collective expertise. To learn more about Cyclica and how we partner, please visit www.cyclicarx.com.
About Oncocross
Oncocross is a Seoul based AI biotech company focused on drug development based on transcriptome database. Oncocross partners with pharmaceutical companies to develop treatments for intractable and rare disease both in oncology and non-oncology space by i) identifying the optimal indications of NCE under development, ii) identifying the proper indications for clinical stage failed compounds, iii) screening combination drugs that can significantly increase the efficacy synergistically, iv) finding the optimal cancer biomarker, and v) screening the optimal drug candidate for selected disease indication. For more information, please visit www.oncocross.com or www.linkedin.com/company/oncocross-co-ltd
Forward Looking Information
This press release contains forward-looking statements and forward-looking information which include, among other things, plans to advance one or more drug discovery programs by Cyclica and Oncocross. Such statements and information are based on management’s beliefs and assumptions and on information currently available to management, and involve risks, uncertainties and other factors that may cause actual results performance or achievements to be materially different from that expressed or implied by these forward-looking statements and information. Although we believe that we have a reasonable basis for each forward-looking statement and forward-looking information contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. We cannot assure you that the forward-looking statements and forward-looking information in this press release will prove to be accurate.